biotech · Cervical Spinal Cord Injury · Spinal Cord Injury · LCTX
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cor
Carlsbad, USA HQ
1990 Founded
35 Employees
Public company Type
LCTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Founded
- 1990
- Employees
- 35
- Programs
- 3
- Drugs
- 0
- Patents
- 0
GRNOPC1
Phase 1 · mab · Spinal Cord Injury
GRNOPC1 for Spinal Cord Injury is a Phase 1 program (mab) at Lineage Cell Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CP35A007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lineage Cell Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- Spinal Cord Injury
- Status
- completed
- Trials
- 1